Today: 7 February 2026
Subscribe

Why Caris Life Sciences (CAI) stock is down today as biotech slips

Why Caris Life Sciences (CAI) stock is down today as biotech slips

NEW YORK, December 30, 2025, 14:58 ET — Regular session Caris Life Sciences shares were down about 1.8% at $27.44 as of 2:41 p.m. ET, after trading between $27.00 and $27.97 during Tuesday’s session. The drop came as biotech stocks underperformed, with the SPDR S&P Biotech ETF down about 1.5% and the iShares Nasdaq Biotechnology ETF off about 1.2%. The S&P 500 was little changed and the Nasdaq was flat, Reuters data showed. Reuters That matters for Caris because the newly public cancer diagnostics company tends to move with shifts in risk appetite for healthcare growth names, even when there
30 December 2025
···
Lululemon stock slips today as founder Chip Wilson launches proxy fight over board shake-up

Lululemon stock slips today as founder Chip Wilson launches proxy fight over board shake-up

NEW YORK, December 30, 2025, 14:50 ET — Regular session Shares of lululemon athletica inc. fell about 0.6% to $211.30 in afternoon trading on Tuesday after founder Chip Wilson launched a proxy fight — a campaign to win shareholder votes for board seats — seeking to reshape the board. The stock had gained about 2% on Monday, Reuters reported. Reuters The board fight comes as the athletic apparel maker searches for a permanent chief executive after Calvin McDonald said he would step down on Jan. 31. Chief financial officer Meghan Frank and chief commercial officer André Maestrini are set to
30 December 2025
·····
Why Cogent Biosciences stock is down today after its FDA filing for bezuclastinib

Why Cogent Biosciences stock is down today after its FDA filing for bezuclastinib

NEW YORK, December 30, 2025, 14:40 ET — Regular session Shares of Cogent Biosciences, Inc. fell 2.7% to $36.88 on Tuesday after the biotech said it submitted a New Drug Application to the U.S. Food and Drug Administration for its drug candidate bezuclastinib in nonadvanced systemic mastocytosis. Yahoo Finance An NDA is the formal request asking the FDA to review a drug for marketing approval, a key inflection point for development-stage biotechs with no products on the market. U.S. Food and Drug Administration Systemic mastocytosis is a rare disorder marked by abnormal accumulation and activation of mast cells — immune
30 December 2025
·····
Amgen stock dips as Lumakras combo trial ends; MariTide data now the next watch

Amgen stock dips as Lumakras combo trial ends; MariTide data now the next watch

NEW YORK, December 30, 2025, 2:56 PM ET — Regular session Amgen Inc. shares were down 0.4% at $328.32 at 2:56 p.m. ET on Tuesday, after trading between $325.90 and $330.18. The modest move matters because investors are grading Amgen’s pipeline for new growth while several mature products face price pressure and biosimilar competition. Oncology and obesity remain two key swing factors for the stock heading into 2026. Biotech stocks lagged, with the iShares Nasdaq Biotechnology ETF down about 1.1%, while the healthcare sector ETF was roughly flat and the S&P 500 ETF hovered near unchanged. Verastem Oncology said it
30 December 2025
·····
Texas Instruments stock today: TXN flat after ReRAM licensing deal as Fed minutes land

Texas Instruments stock today: TXN flat after ReRAM licensing deal as Fed minutes land

NEW YORK, December 30, 2025, 14:44 ET — Regular session Texas Instruments Incorporated (TXN) shares were little changed on Tuesday after memory developer Weebit Nano said it had licensed its resistive random access memory, or ReRAM, technology to the chipmaker. The stock was down about 0.01% at $175.67 in afternoon trade, and TI executive Amichai Ron said the partnership would give customers access to “industry-leading NVM technology.” Weebit The announcement matters because embedded non-volatile memory — storage that keeps data when power is off — is a key building block for chips that run cars, factory equipment and other electronics
30 December 2025
······
Mastercard stock dips in thin year-end trade as Fed minutes sharpen rate focus

Mastercard stock dips in thin year-end trade as Fed minutes sharpen rate focus

NEW YORK, December 30, 2025, 14:45 ET — Regular session Mastercard Incorporated shares were down 0.3% at $576.37 in afternoon trading on Tuesday, after moving between $574.55 and $579.49 earlier in the session. Volume was about 683,000 shares. The small move still matters into year-end because investors use card networks as a bellwether for consumer spending. Mastercard earns fees when transactions run across its network, so shifts in shopping and travel can show up quickly in volume trends. Rates are also front and center for the group. Payment processors trade like high-quality growth stocks inside financials, which can make them
30 December 2025
·····
Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3%

Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3%

NEW YORK, December 30, 2025, 14:45 ET — Regular session Arcutis Biotherapeutics shares fell 2.9% to $27.74 in afternoon trading on Tuesday, after moving between $27.72 and $28.65. Volume was about 0.6 million shares. The drop outpaced broader biotech gauges, with the SPDR S&P Biotech ETF down about 1.5% and the iShares Nasdaq Biotechnology ETF off about 1.1%. That matters for Arcutis because it trades as a growth story tied to one product franchise, leaving the stock prone to outsized moves when sentiment sours across biotech and high-multiple names. Arcutis is a commercial-stage medical dermatology company whose main product, Zoryve
30 December 2025
·····
Accenture stock slips as Argus cuts target; Fed minutes keep Wall Street cautious

Accenture stock slips as Argus cuts target; Fed minutes keep Wall Street cautious

NEW YORK, December 30, 2025, 14:33 ET — Regular session Accenture plc shares were down about 0.5% on Tuesday, drifting lower in a quiet year-end session after Argus lowered its price target on the IT services company while maintaining a buy rating. The move matters because Accenture is widely treated as a read-through on corporate technology spending, and late-December liquidity is thin. In that backdrop, even routine changes in analyst targets can move large-cap consulting names more than usual. Traders were also navigating a fresh macro signal after Federal Reserve meeting minutes showed policymakers split over how quickly to keep
30 December 2025
·····
Vera Therapeutics stock drops 3% today as biotech slips into year-end trading

Vera Therapeutics stock drops 3% today as biotech slips into year-end trading

NEW YORK, December 30, 2025, 2:26 PM ET — Regular session Vera Therapeutics, Inc. shares slid 3.4% to $50.45 in afternoon trading on Tuesday, giving back some recent gains as biotech stocks softened late in the year. The move matters now because Vera has become a bellwether “event-driven” biotech name, where day-to-day trading can swing sharply as investors calibrate risk around FDA timelines and competitive positioning in kidney disease. Thin year-end liquidity can amplify those swings, and traders have been quick to trim exposure to smaller, higher-beta healthcare names when the sector loses momentum. Minutes from the Federal Reserve’s December
30 December 2025
······
Rigetti stock today: RGTI steadies as Fed minutes and year-end flows keep quantum names jumpy

Rigetti stock today: RGTI steadies as Fed minutes and year-end flows keep quantum names jumpy

NEW YORK, December 30, 2025, 14:34 ET — Regular session Rigetti Computing shares edged up 0.3% to $22.34 on Tuesday afternoon, after swinging about 3% between the day’s high and low. IonQ rose 1.2% and D-Wave Quantum gained 1.6%. The muted move matters because quantum-computing stocks have become a high-beta pocket of the market, prone to sudden swings when liquidity thins and rate expectations shift. With the calendar turning, traders are re-pricing how much room the Federal Reserve has to ease in 2026. U.S. stocks were subdued in holiday-thin trading, with investors rotating within technology after a late-year run-up, Reuters
30 December 2025
·······
Ares Management stock drops 3% in New York as Fed minutes hit year-end trading

Ares Management stock drops 3% in New York as Fed minutes hit year-end trading

NEW YORK, December 30, 2025, 2:20 PM ET — Regular session Shares of Ares Management Corp fell 3.1% to $163.85 in afternoon trading on Tuesday, down $5.20 from Monday’s close. The stock traded between $168.99 and $163.49, with about 966,000 shares changing hands. The move matters because Ares is closely tied to credit-market conditions. Investors are weighing where interest rates settle in early 2026 and what that means for fundraising, deal activity and returns in private credit. A Reuters Breakingviews column said private credit is losing some of its pricing edge as bank-led bond and loan markets regain momentum, pushing
30 December 2025
····
AT&T stock today ticks higher as Fed minutes loom and year-end rotation lifts telecoms

AT&T stock today ticks higher as Fed minutes loom and year-end rotation lifts telecoms

NEW YORK, December 30, 2025, 14:35 ET — Regular session AT&T Inc shares were up 0.1% at $24.80 in afternoon trade on Tuesday, hovering near the top of a tight day range as the broader market struggled for direction. The stock traded between $24.75 and $24.85. The move matters because income-heavy telecom stocks often trade with interest-rate expectations at year-end, when many investors rebalance portfolios. The yield on the 10-year U.S. Treasury note rose 1.8 basis points — a basis point is 0.01 percentage point — to 4.134%, and traders were awaiting the Federal Reserve’s meeting minutes later in the
30 December 2025
·········
1 … 1,080 1,081 1,082 1,083 1,084 … 2,710

Stock Market Today

Rio Tinto stock drops in early London trade after Glencore deal talks collapse

Rio Tinto stock jumps as Glencore mega-merger is shelved; what to watch next week

7 February 2026
New York, Feb 7, 2026, 02:50 EST — Market closed Rio Tinto’s U.S.-listed shares closed higher on Friday after the miner said it would not pursue a merger with Glencore, ending weeks of deal talk that had hung over the sector. The stock finished at $93.37, up about 2.5% on the day. (https://finance.yahoo.com/quote/RIO/history/) The move matters because the market had started to price in a rare industry shake-up — and the risk that Rio might have to pay up to get it done. By walking away, Rio removed one uncertainty but left investors with the same old question: can it
iFAST share price drops 3% as markets shut; earnings next week in focus

iFAST share price drops 3% as markets shut; earnings next week in focus

7 February 2026
iFAST shares fell 3.2% to S$9.64 in heavy trading Friday, closing near the day’s low as investors awaited FY2025 results due Feb. 12. The stock is about 13% below its 52-week high. iFAST recently agreed to buy a 30% stake in Financial Alliance for S$19.6 million, pending regulatory approval. Assets under administration stood at S$30.62 billion as of Sept. 30.
Sembcorp Industries share price: what to watch after Friday dip as Feb 25 results near

Sembcorp Industries share price: what to watch after Friday dip as Feb 25 results near

7 February 2026
Sembcorp shares closed at S$6.05 on Friday, down 0.33%, as Singapore’s STI dropped 0.8%. Shareholders approved the A$6.5 billion Alinta Energy takeover on Jan 30, but the deal still faces regulatory and closing conditions. Sembcorp will release FY2025 results on Feb 25 before market open. Trading volume reached about 4.3 million shares.
Go toTop